Director message
The Centre
The Team
The Researchers
The Employees
Laboratories
Platforms
Infectio Zone



    Afficher cette page en français  

Michel G.Bergeron, O.Q., M.D., FRCPC

Director, Division of Microbiology and
Le Centre de Recherche en Infectiologie
de L'université Laval

Address :

Centre de recherche en infectiologie du CHUL
2705, boul. Laurier,
Québec (Québec), Canada,
G1V 4G2
 
Phone : (418) 654-2705
Fax : (418) 654-2715
 
E-mail : Michel.G.Bergeron@crchul.ulaval.ca


Home




Dr. Michel G. Bergeron is a full Professor and Chairman of the Division of Microbiology and of the Infectious Diseases Research Centre of Laval University in Québec city, which he founded in 1974. He completed a postdoctoral fellow in microbiology and infectious diseases at Tufts University and at the Massachusetts Institute of Technology, in Boston. Dr. Bergeron is the author or co-author of 364 scientific articles, 44 book chapters, 969 communications in congresses and invited speaker at international symposiums, and he acted as chairman in 80 symposiums.  Dr Bergeron holds 15 patents and is the recipient of more than 50 million $ grants as principal investigator or co-investigator. His main research projects consist in the development of DNA-based diagnostic tests for the detection of microbes and their associated antibiotic resistance genes in less than one hour compared to the >48 hours still requested in conventional microbiology laboratories today. To perform this, Dr Bergeron created Infectio Diagnostic, which merged with B-D Diagnostic-GeneOhm. Three of the tests he has developed are already on the market, for the detection of streptococci, staphylococci, and enterococci. By combining genomics, DNA microarrays, microfluidic networks, and nanotechnology, Dr Bergeron is developing a ‘compact disk’ that will allow simultaneous detection of various microbes within 15 minutes at the point-of-care, based on their DNA fingerprints. To achieve this goal, Dr Bergeron has created GenePOC, a company dedicated to the development of new diagnostic tools. Dr Bergeron has also developed a microbicidal gel, the Invisible Condom®, to prevent women from contracting HIV/AIDS and other sexually transmitted diseases. A phase III clinical trial is being prepared to confirm the efficacy of this product. Dr Bergeron has also been working on several topics including the pathogenesis of pneumonia and the use of immunomodulator drugs to control inflammation. In recognition of his outstanding scientific career and for life-time achievements, Dr Bergeron was recently nominated Officer of the ‘Ordre du Québec’ received by the premier of the Province of Québec; he was the Laureate of the ‘Transfer Award’ at the 11th edition of the Innovation-Research Contest 2008 of the Association of Health Technologies Industry; Laureate of the 2007 Genome Quebec’s ‘Biotechnology Award of Tomorrow’ at Genesis Awards Gala; Laureate of the ‘Wilder-Penfield prize’ (Prix du Québec), the highest distinction of the Government of the Province of Québec for outstanding achievements in biomedical research; Laureate of the ‘Prix de l'œuvre scientifique’ by the Association des Médecins de langue française du Canada; Recipient of the ‘Prix Louis Pasteur’ and of the ‘Médecin de mérite’ award.